MGAT2-IN-7
MGAT2-IN-7 is an orally active monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3115123-06-0
- Formule: C31H30F3N3O6S
- Masse moléculaire:629.65
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
MGAT2-IN-7 (compound 27Q) potently inhibits human monacylglycerol acyltransferase 2 with an IC50 of <1 μM in an in vitro thiol-fluorescence enzyme assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MGAT2-IN-7 (50 mg/kg; p.o.; daily; 22 days) synergistically enhances weight loss and food intake reduction when combined with GLP-1 receptor agonists in diet-induced obese mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (male, 16 weeks old, diet-induced obese)[1]
-
Dosage:15 mg/kg; 50 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Reduced average body weight by 1.39 g (3.6%) over 7 days, with 10% less 24-hour food intake and 9% less 7-day cumulative food.
Reduced average body weight by 2.5 g (6.8%) over 7 days, with 17% less 24-hour food intake and 20% less 7-day cumulative food.
-
Animal Model:C57BL/6J mice (male, diet-induced obese)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; daily; 22 days
-
Result:Increased body weight reduction from -17.8% (tirzepatide alone) to -38% at 17 days and reduced cumulative food intake by 84% relative to vehicle controls (a 4-fold additional reduction over tirzepatide alone) when combined with maximum dose tirzepatide.
Increased body weight reduction from -32% (semaglutide alone) to -74.3% at 17 days and reduced cumulative food intake by 77% relative to vehicle controls (a 3.3-fold additional reduction over semaglutide alone) when combined with maximum dose semaglutide.
All differences were statistically significant.
Chemical Information
-
CAS No. 3115123-06-0
-
Masse moléculaire 629.65
-
Formule C31H30F3N3O6S
-
SMILES
CC1=CC=C(C(C2=CC=C(C=N2)COC3CCN(CC3)C4=CC=C(C=C4)OC(F)(F)F)=C1)S(=O)(NC(C5=CC=C(O5)C)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MGAT2-IN-7 Related Classifications
HY-181564 Related Classifications
Powered by Bioz